Veriti Management LLC Has $897,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Veriti Management LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 5.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 15,096 shares of the biopharmaceutical company’s stock after buying an additional 783 shares during the quarter. Veriti Management LLC’s holdings in Gilead Sciences were worth $897,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Norges Bank acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $950,911,000. Capital World Investors grew its holdings in shares of Gilead Sciences by 15.4% during the 4th quarter. Capital World Investors now owns 42,681,624 shares of the biopharmaceutical company’s stock worth $3,099,157,000 after purchasing an additional 5,705,315 shares in the last quarter. EP Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 72,909.8% during the 3rd quarter. EP Wealth Advisors LLC now owns 3,613,253 shares of the biopharmaceutical company’s stock worth $322,000 after purchasing an additional 3,608,304 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Gilead Sciences by 65.1% during the 4th quarter. Renaissance Technologies LLC now owns 9,082,069 shares of the biopharmaceutical company’s stock worth $659,449,000 after purchasing an additional 3,581,114 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Gilead Sciences by 4.0% during the 4th quarter. State Street Corp now owns 57,369,269 shares of the biopharmaceutical company’s stock worth $4,165,583,000 after purchasing an additional 2,187,144 shares in the last quarter. 80.16% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Gilead Sciences stock opened at $61.51 on Thursday. The company has a quick ratio of 1.30, a current ratio of 1.48 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a 12 month low of $57.17 and a 12 month high of $74.12. The business has a fifty day simple moving average of $61.98 and a 200 day simple moving average of $64.15. The stock has a market cap of $77.15 billion, a PE ratio of 17.18, a price-to-earnings-growth ratio of 0.59 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILDGet Rating) last announced its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $2.12 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.35. Gilead Sciences had a return on equity of 44.98% and a net margin of 16.43%. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.28 billion. During the same period in the previous year, the firm earned $2.08 earnings per share. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Analysts expect that Gilead Sciences, Inc. will post 6.59 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 29th. Shareholders of record on Wednesday, June 15th will be paid a $0.73 dividend. The ex-dividend date is Tuesday, June 14th. This represents a $2.92 dividend on an annualized basis and a yield of 4.75%. Gilead Sciences’s payout ratio is 81.56%.

Several analysts have recently weighed in on the company. Barclays decreased their price objective on Gilead Sciences from $63.00 to $56.00 and set an “underweight” rating on the stock in a report on Thursday, March 10th. Wells Fargo & Company cut their target price on Gilead Sciences from $70.00 to $63.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 22nd. Morgan Stanley cut their target price on Gilead Sciences from $69.00 to $63.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 12th. SVB Leerink started coverage on Gilead Sciences in a research report on Monday, May 23rd. They set a “market perform” rating and a $68.00 target price for the company. Finally, BMO Capital Markets started coverage on Gilead Sciences in a research report on Tuesday, June 7th. They set a “hold” rating and a $63.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Hold” and an average target price of $72.07.

Gilead Sciences Company Profile (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Recommended Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Want More Great Investing Ideas?

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.